Behavioural characterization of prodynorphin knockout mice by Schunk, Eduard et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
BMC Pharmacology
Open Access Meeting abstract
Behavioural characterization of prodynorphin knockout mice
Eduard Schunk1, Iris Rosskothen1, Walter Wittmann1, Stefano Gaburro2, 
Nicolas Singewald2, Herbert Herzog3 and Christoph Schwarzer*1
Address: 1Department of Pharmacology, Innsbruck Medical University, 6020 Innsbruck, Austria, 2Department of Pharmacology and Toxicology, 
University of Innsbruck, 6020 Innsbruck, Austria and 3Garvan Institute of Medical Research, Sydney, New South Wales 2010, Australia
Email: Christoph Schwarzer* - schwarzer.christoph@i-med.ac.at
* Corresponding author    
Dynorphin, with a high selectivity for kappa opioid recep-
tors, is a member of the opioid peptide family. Applica-
tion of opioid agonists and antagonists revealed crucial
effects of the opioid system in numerous physiological
functions. However, data obtained are often contradic-
tive, reflecting the complex situation of the cross-activa-
tion of 3 receptors through a peptide derived from 3
different precursors. Therefore we investigated prodynor-
phin knockout mice (DynKO) to establish the effect of
prodynorphin deficiency on explorative behaviour in
mice. DynKO exhibited higher ambulation in the open
field test. Thus, center distance, center time and number
of center entries were increased about 2-fold, and number
of center rearings about 3-fold. DynKO mice showed also
more visits (~2-fold) and more time (~3-fold) spent on
open arms of the elevated plus maze test. Significantly
higher numbers of entries, distance and time spent in
open lit area (ca. 30% higher values) in the light-dark test
were observed in DynKO as compared to wild type mice
(WT). In contrast to increased explorative behaviour of
DynKO under aversive conditions, no differences in
motor activity or circadian rhythms were observed in the
home cage. The anxiolytic phenotype of DynKO could be
mimicked by injection of the selective kappa antagonists
norBNI (10 mg/kg, i.p.) or GNTI (3 nmol, i.c.) in WT.
Applying the specific kappa agonist U50488 H (2.5 mg/
kg, i.p.) entirely reversed the anxiolytic phenotype of
DynKO. Taken together our data clearly show an anxio-
lytic phenotype of male DynKO mice. These data are in
line with reduced CRH expression in the PVN and attenu-
ated corticosteron serum levels.
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